Tiger Brokers

Perspective's Cancer Therapy Candidate Receives FDA Fast Track Designation; Shares Rise Pre-Bell

MT Newswires Live
3 hours ago

Perspective Therapeutics (CATX) said Thursday that the US Food and Drug Administration, or FDA, granted fast track designation for the development of PSV359, an experimental cancer treatment for adults with advanced tumors that cannot be removed through surgery or have spread to other parts of the body.

The investigational therapy is being studied in an ongoing Phase 1/2a trial in patients with advanced fibroblast activation protein-positive solid tumors, the company said.

The company said early human imaging data showed strong tumor uptake and rapid kidney clearance for PSV359.

The FDA's fast track program is aimed at accelerating the development and review of therapies for serious conditions with unmet medical needs, the company added.

Shares rose around 4.9% in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10